Suggested remit: To appraise the clinical and cost effectiveness of nivolumab in combination with ipilimumab within its marketing authorisation for untreated advanced unresectable recurrent or metastatic oesophageal cancer.
Status Proposed
Process STA 2018
ID number 1629

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 16 April 2021 - 17 May 2021

Project Team

Project lead Michelle Adhemar

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance